A qualitative classification signature for post-surgery 5-fluorouracil-based adjuvant chemoradiotherapy in gastric cancer

Highlights: • We developed a classification signature to accurately classify GC patients who may benefit from 5-FU-based ACRT. • The 34-GPS was not a signature for GCs treated with surgery alone and 5-FU based chemotherapy alone. • The signature can be applied in an individual level, which could aid clinicians in tailoring more effective GC treatments. Currently, 5-fluorouracil (5-FU)-based adjuvant chemoradiotherapy (ACRT) is a preferred regimen for post-surgery gastric cancer (GC). However, the survival outcome of 5-FU-based ACRT varies greatly among different GC patients. Thus, it is necessary to classify which patients may benefit from 5-FU-based ACRT.